瘤体注射表皮生长因子受体抗体治疗小鼠宫颈癌

Treatment of cervical carcinoma in mice by injecting monoclonal antibody of epidermal growth factor receptor into solid tumor

目的 :观察阻断表皮生长因子受体是否治疗小鼠宫颈癌。方法 :将小鼠宫颈癌细胞U14(1× 10 7)移植入近交系 6 15系小鼠皮下 ,待成瘤后将 2 4只小鼠随机分为 4组 ,用表皮生长因子受体单克隆抗体 (EGFR -McAb)瘤体局部注射 (每天 1次 ,连续 2周 )治疗A和B组 ,用生理盐水对照治疗对照A和对照B组。观察治疗A及对照A组小鼠的生存期和肿瘤的抑瘤率。并取治疗后第 4,7,10 ,14,16 ,17d处死的治疗B组及对照B组小鼠瘤体组织作血管内皮标记物CD31免疫组化染色 ,计算肿瘤内平均微血管密度。结果 :用EGFR -McAb治疗A组平均生存期 42 .8d ,较对照组 2 8.3d明显延长 (P <0 .0 1)。治疗A组肿瘤抑瘤率第 4d为 13% ,第 7d为 42 % ,第 10～ 14d达高峰 ,维持在 83% 84%。第 7,10 ,14d治疗A组与对照A组瘤体体积差异显著 (P <0 .0 5 )。治疗组肿瘤内微血管密度明显低于对照组(P <0 .0 5 )。结论 :EGFR -McAb可有效治疗小鼠宫颈癌 ,提示其可作为宫颈癌导向治疗的候选靶分子。

Objective To observe the effect of treating cervical carcinoma in mice by injecting monoclonal antibody of epidermal growth factor receptor (EGFR-McAb) into solid tumor. Methods Six hundred and fifteen strain mice bearing U14 cervical cancer cell were subcutaneously injected with EGFR-McAb in Group A and B. The mice in control Group A and B were injected with 0.9% sodium chloride instead of EGFR-McAb. The volume of the tumor in Group A as measured for 2 weeks consecutively. The survival time of the mice both in Group A and in control Group A were observed. The mice in Group B were killed in the 4th,7th,10th,14th,16th, and 17th days.Tissue section of the tumor as stained immunohistochemically for CD31.Active areas of angiogenesis chosen under microscope and average microvessels counted per field(40×) were taken as intratumor microvessel density(IMD). Results (1) The mean survival time in Group A was 42.8 day while in control Group A it was 28.3 day. (2) The tumor growth inhibitory rate in Group A in the 4th,7th,10th ,and 14th days was 13%,42%,83%, and 84%,respectively,and in the 7th, 10th and 14th days there was a significant difference(P<0.05). (3) The Group B was 15.6±4.0,while in control Group B it was 31.1±14.6. The average IMD in the Group B was lower than that in the control Group B. Conclusions An effective treatment to cervical cancer in mice can be made with EGFR-McAb. It is suggested that EGFR-McAb may be a target for treating cervical cancer.